Out of Patients EP453: Mission, Margin, and the Women Left Waiting: Vasanta Pundarika

Healthcare has spent the last decade rediscovering women the way cable television rediscovered acoustic music after Nirvana unplugged. Suddenly every investor presentation features maternal health, menopause, behavioral health, fertility, longevity, hormonal care, and “whole person” language wrapped in pastel branding and soft lighting. Capital finally noticed that women make most healthcare decisions, absorb most caregiving responsibility, and represent an enormous commercial market.

The timing looks compassionate. The incentives look commercial. Both can be true simultaneously.

That tension sat underneath my conversation with Vasanta Pundarika, a former healthcare investment banker who spent nearly 20 years advising healthcare systems, behavioral health companies, and provider organizations before launching Lotuspring, an advisory firm focused on women’s health and behavioral health. What made the conversation useful had less to do with ideological positioning and more to do with operational honesty. She understands how capital behaves because she spent most of her career inside the rooms where healthcare growth gets financed, structured, and sold.

That perspective matters because healthcare reform conversations often collapse into caricature. One side frames private capital as predatory by definition. The other frames scale as inherently virtuous. Neither position explains how the system actually behaves under pressure.

The American healthcare system behaves rationally according to its incentives. Investors seek scalable returns. Health systems seek margin preservation. Employers seek predictable costs. Insurers seek utilization control. Patients seek survival, access, and financial stability. The friction emerges when those incentives collide without aligned accountability.

Women’s health exposes that collision clearly because the system historically optimized around assumptions that no longer reflect how people live.

One of the most revealing moments in the conversation came when Vasanta described what behavioral health providers saw during COVID. Men’s residential treatment units filled back up faster than women’s units. Many executives interpreted the disparity operationally. Lower utilization. Slower recovery. Delayed demand. Vasanta interpreted it socially. Women remained home caring for children, parents, spouses, jobs, and households while delaying their own treatment.

That observation sounds obvious once stated plainly. Which raises the uncomfortable question. Why did healthcare infrastructure fail to anticipate it?

The answer sits inside incentive design.

American healthcare still operates around a patient model built decades ago around male workforce assumptions. The system assumes patients possess flexible schedules, transportation, childcare, administrative literacy, stable employment, and enough emotional bandwidth to navigate fragmented care delivery. Women routinely absorb the gap between those assumptions and reality.

Caregiving labor remains economically invisible despite carrying enormous system value. The United States depends on unpaid caregiving to subsidize the healthcare system quietly. Families provide transportation, medication management, care coordination, meal preparation, recovery supervision, emotional support, and administrative navigation without reimbursement. Women perform most of that labor.

Healthcare accounting systems rarely price its absence until crisis emerges.

That matters economically because delayed care compounds downstream costs. Behavioral health deterioration increases emergency utilization, inpatient admissions, disability claims, workforce instability, and long term medical spending. The system eventually pays either way. It simply chooses whether to pay earlier through accessible care or later through crisis response.

The same pattern appears throughout women’s health more broadly.

For decades, women’s health largely meant reproductive care operationally. Fertility. Pregnancy. OB GYN services. That narrow framing ignored cardiovascular disease, autoimmune disorders, chronic pain, hormonal health, menopause, mental health, and the cumulative impact of caregiving stress itself. Research funding, reimbursement structures, clinical trial design, and diagnostic frameworks reflected those priorities.

Now capital has entered aggressively because investors finally recognize the market opportunity surrounding those neglected categories.

Some of that investment will improve care materially. Some will generate sophisticated marketing layered over operational mediocrity.

Vasanta used a phrase in another interview that captured the distinction well. “Snazzy big brands.” Every healthcare insider immediately understands the type. Companies that scale branding faster than clinical infrastructure. Beautiful websites. Impressive investor decks. Carefully managed thought leadership. Patient experience language polished within an inch of its life. Then the actual operational experience collapses into understaffing, fragmented care coordination, aggressive utilization targets, or prior authorization paralysis.

The problem does not originate from greed alone. It originates from misaligned incentives around what markets reward.

Healthcare startups often face pressure to demonstrate rapid growth before demonstrating durable outcomes. Investors seek scalable operational models because scale determines valuation. Founders seek additional funding rounds because healthcare delivery requires enormous capital intensity. Health systems seek acquisition targets that improve revenue diversification. The market rewards growth visibility faster than clinical maturity because growth visibility appears easier to measure.

Patient trust erodes inside that gap.

Healthcare executives frequently underestimate how fragile trust actually becomes after administrative harm. Patients experience billing confusion, prior authorization delays, fragmented communication, inaccessible scheduling, and inconsistent follow through as signals of institutional unreliability. Executives often classify those failures operationally. Patients experience them existentially.

I learned that lesson personally during brain cancer treatment at 21. My father handled most of the insurance fights and administrative navigation because survival itself consumed my available bandwidth. That division of labor protected me physically at the time. It also revealed how dependent serious illness becomes on invisible administrative caregiving. Patients without that support structure face radically different outcomes even with identical diagnoses.

Healthcare markets still struggle to account for that reality because administrative burden remains distributed unevenly across families rather than concentrated directly on institutional balance sheets.

That creates distorted economic feedback loops.

When prior authorization delays chemotherapy, the insurer may temporarily preserve short term utilization control. The patient absorbs emotional stress, clinical uncertainty, transportation disruption, missed work, and potential disease progression risk. Families absorb caregiving strain. Employers absorb productivity loss. Emergency systems absorb downstream complications. The cost never disappears. It simply migrates across stakeholders until the least powerful participants absorb the friction.

Behavioral health demonstrates the same dynamic vividly.

The United States underinvested in behavioral health infrastructure for decades while social isolation, addiction, burnout, trauma, and economic instability worsened steadily. Now investors view behavioral health as a major growth category because demand has exploded. Again, both realities can coexist. Increased capital can expand access meaningfully. Poorly governed capital can also commoditize vulnerability rapidly.

That distinction depends heavily on operational accountability.

Many healthcare leaders defend consolidation and scale by arguing correctly that fragmented systems create inefficiency. They are right. Small providers often struggle with reimbursement pressure, staffing shortages, technology costs, regulatory compliance, and payer negotiations. Scale can improve administrative efficiency, negotiating leverage, geographic reach, and integrated care delivery.

Scale also creates pressure for standardized operational targets that may conflict with individualized care.

The conversation should focus less on whether capital belongs in healthcare and more on how incentives shape behavior once capital enters the system. Capital itself remains morally neutral. Incentive structures determine whether organizations optimize for long term patient stability or short term financial extraction.

That distinction explains why some healthcare companies maintain trust while others deteriorate quickly after acquisition or expansion.

Organizations that preserve trust typically align reimbursement, staffing, quality metrics, and executive incentives around long term outcomes rather than short term utilization volume alone. Organizations that destroy trust usually create operational pressure points where financial targets override clinical discretion quietly. Patients rarely see those decisions directly. They experience the downstream effects through rushed visits, delayed approvals, inaccessible clinicians, or fragmented coordination.

Healthcare reform discussions often fail because participants argue morality while avoiding incentive architecture.

Most executives do not wake up seeking patient harm. Most investors do not explicitly pursue worse outcomes. Most clinicians do not enter medicine seeking administrative warfare. The system produces predictable behavior because institutions respond rationally to financial structures surrounding them.

That means reform requires economic realignment more than moral performance.

If policymakers want earlier behavioral health intervention, reimbursement must support it sustainably. If employers want lower long term healthcare costs, benefits design must reduce administrative barriers to preventative care. If investors want durable healthcare companies, markets must reward patient retention and outcomes alongside revenue growth. If regulators want trust restoration, they must create transparency around utilization management, network adequacy, and administrative burden.

None of that requires abandoning markets. It requires building better incentives inside them.

The healthcare industry currently spends enormous energy discussing innovation while underestimating operational credibility. Patients rarely evaluate systems ideologically during crisis. They evaluate systems practically. Can they access care quickly? Can they understand the bill? Can they trust the recommendation? Can they keep their job while receiving treatment? Can they survive financially while surviving medically?

Those questions determine legitimacy more than branding campaigns ever will.

Vasanta’s value as a voice inside this conversation comes from her ability to recognize both the necessity and danger of scale simultaneously. She understands capital allocation. She also understands that healthcare routinely misunderstands human behavior while pretending data alone explains outcomes.

That misunderstanding carries enormous economic consequences.

The future of healthcare will depend less on whether more capital enters women’s health and behavioral health and more on whether institutions finally learn to design systems around how people actually live instead of how spreadsheets assume they live.